The contemporary management of acute myocardial infarction

Critical Care Clinics

Volumn 17, Issue 2, 2001, Pages 411-434

  Almeda, Francis Q ^b   Snell, R Jeffrey ^b   Parrillo, Joseph E ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANISTREPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LAMIFIBAN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TIROFIBAN;

ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CORONARY REPERFUSION; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; MORTALITY; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0034952271     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70175-5     Document Type: Article

References (69)

1. Prevalence of angiographically significant stenosis in patients with chest pain and an elevated troponin I level and normal creatine kinase and creatine kinase MB levels
2. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
3. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarctions (TIMI) 11B trial
4. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
5. Single-bolus tenecteplase compared with front-loaded alteplase in acute MI: The ASSENT-2 double-blind randomized trial
6. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front loaded accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
7. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
8. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction (RAPPORT)
9. Six month clinical and angiographic follow up after direct angioplasty for acute myocardial infarction: Final results from the Primary Angioplasty Registry
10. Validated risk stratification model accurately predicts low risk in patients with unstable angina
11. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose ranging trial
12. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina
13. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
14. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial (Thrombolysis in Myocardial Ischemia)
15. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
16. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
17. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
18. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1
19. How big are the coronary atherosclerotic plaques that rupture?
20. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II Prospective Randomized Multicenter Study
21. Insights into the pathogenesis of acute ischemic syndromes
22. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction
23. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
24. A factorial randomised trial of alterplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
25. Effects of lisinopril and transdermal glycerl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico
26. A comparison of reteplase with alteplase for acute myocardial infarction
27. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
28. Coronary angioplasty with or without stent implantation for acute myocardial infarction
29. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
30. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction
31. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
32. Should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) investigators: Early revascularization in acute MI complicated by cardiogenic shock
33. Cardiogenic shock
34. Randomised placebo-controlled trial of the effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
35. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
36. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction
37. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction
38. Platelet glycoprotein IIb/IIIa recepors in cardiovascular medicine
39. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: Pharmacokinetic evaluation from in-TIME study
40. Metoprotol in Acute MI (MIAMI): A randomised placebo controlled international trial
41. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
42. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIB/IIIa inhibitor), heparin, or both in unstable angina
43. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after MI
44. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
45. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction
46. Inhibition of platelet glycoprotein IIb/IIIa with eptifibitide in patients with acute coronary syndromes
47. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac event rates in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
48. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction
49. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: Immediate and long-term results
50. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
51. Immediate vs. deferred beta-blockade following thrombolytic therapy in patients with acute MI: Results of TIMI II-B
52. New plasminogen activators: A clinical review
53. Extended mortality benefit of early postinfarction reperfusion
54. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction
55. Importance of antithrombin therapy in combination with abciximab and low dose fibrinolytic therapy: Preliminary results of the GUSTO IV pilot study
56. Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy
57. Aspirin, heparin, or both to treat acute unstable angina
58. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
59. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: The ASSENT-1 trial
60. Coronary thrombolysis
61. Low-molecular weight heparins
62. Overview of results of randomized clinical trials in heart disease II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification
63. Randomized comparison primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction
64. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction